Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Epistemonikos ID: 95ec1902edab387a74e38a5eaca46b56d1480d56
First added on: May 12, 2024